Melody Cobleigh to Survival Analysis
This is a "connection" page, showing publications Melody Cobleigh has written about Survival Analysis.
Connection Strength
0.236
-
Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs. Clin Cancer Res. 2019 04 15; 25(8):2433-2441.
Score: 0.156
-
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007 Dec 27; 357(26):2666-76.
Score: 0.018
-
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006 Jun 20; 24(18):2786-92.
Score: 0.016
-
Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer. 2005 Aug; 6(3):240-6.
Score: 0.015
-
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol. 2002 Aug 01; 20(15):3317-27.
Score: 0.012
-
First-line Herceptin monotherapy in metastatic breast cancer. Oncology. 2001; 61 Suppl 2:37-42.
Score: 0.011
-
Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation. J Clin Oncol. 1994 Feb; 12(2):342-6.
Score: 0.007